SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is drawing attention amid a selloff that traders link to Piper Sandlers lower price target and concerns that networking growth may be peaking and sector valuations could compress; the firm maintained its Neutral rating. The community is divided between viewing the decline as an overreaction given AI-infrastructure demand and strong results, and seeing weakening momentum as a reason for caution.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick is drawing attention amid a sharp pullback, with repeated Elliott Wave chart calls warning that the correction may have more downside and options activity skewed toward puts. Traders are split between waiting for lower entry points and buying the dip, while longer-term bulls point to gold and miners potential;

First Majestic Silver Corp. engages in the production, development, exploration, and acquisition of mineral properties, with a focus on silver and gold production in North America. It owns and operates producing mines in Mexico, including the Santa Elena Silver & Gold Mine, the Los Gatos Silver Mine, the San Dimas Silver & Gold Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA, which is currently in the process of restarting. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

AG is drawing attention amid volatile silver prices and weakness across precious-metals miners, with traders pointing to rising yields and expectations of tighter Fed policy as headwinds. Some see the pullback as a buying opportunity based on long-term silver supply and demand, while others expect further downside and question when miners will recover.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Takeover speculation is a major topic after reports that Lundbeck explored acquiring Xeris, but no deal is confirmed and the company said it is not for sale; traders disagree over whether interest could lead to an offer. Others are focused on the upcoming Q3 results and Recorlev sales growth, with XP-8121s Phase 3 program viewed as a longer-term catalyst.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention after a steep share-price decline ahead of Q3 results, with investors focused on whether Auvelity salesespecially its Alzheimers agitation launchare accelerating enough to support a path to profitability. Bulls argue prescription data may undercount sampling and long-term-care demand, while bears question the launchs pace, spending and managements lack of clarity.

Pudgy Penguins (PENGU) is a cryptocurrency launched in 2024and operates on the Solana platform. Pudgy Penguins has a current supply of 76,724,221,264.3 with 62,860,396,090.04 in circulation. The last known price of Pudgy Penguins is 0.00754361 USD and is up 6.59 over the last 24 hours. It is currently trading on 540 active market(s) with $130,377,930.32 traded over the last 24 hours. More information can be found at https://www.pengu.pudgypenguins.com.

Pudgy Penguins

Traders are focused on PENGU testing a technical support/buying zone after rejection from a descending channel, debating whether it can bounce or break lower. Some are buying the dip and anticipating a reversal, while others warn of further downside; broader crypto moves, especially Bitcoin, are also seen as influential.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks fiscal Q4 report is driving discussion: earnings and U.S. comparable sales beat expectations, but revenue missed, with the China joint-venture transition weighing on reported international sales. Bulls cite improving traffic and turnaround progress, while bears focus on the revenue miss, weaker international results, and valuation.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,387.69. The last known price of BNB is 703.59425696 USD and is up 0.47 over the last 24 hours. It is currently trading on 3523 active market(s) with $2,735,089,335.64 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

Binances reported multibillion-dollar security breach, attributed in community discussion to a compromised employee device, is driving attention to BNB and raising concerns about exchange security, frozen or inaccessible funds, and possible contagion across crypto. Traders are divided between calls for withdrawals and fears of a wider confidence crisis, and those questioning why BNB and broader crypto have held up relatively well.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline through 2027 has fueled concern about CorMedixs pricing and revenue outlook. Traders are split between treating the comments as a serious risk and viewing DaVitas estimates as preliminary, citing CMSs published rate estimate; reactions include panic selling and dip buying.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devons agreed sale of its Eagle Ford assets to Crescent Energy is drawing attention, as traders weigh whether the divestiture will streamline the portfolio and strengthen the balance sheet. Reactions are mixed: some see value in the sale, while others question why the shares have not responded more positively.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -15.39% and -31.82%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -7.69% and +222.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.09% and +2.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +14.48% and +3.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ProKidney (PROK) to Release Quarterly Earnings on Monday

ProKidney (NASDAQ:PROK) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-prokidney-corp-stock...

ProKidney (NASDAQ:PROK) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded ProKidney from a "strong sell" rating to a "sell" rating in a research report on Saturday...

ProKidney (NASDAQ:PROK) Stock Price Up 9% - Should You Buy?

ProKidney (NASDAQ:PROK) Trading 9% Higher - Here's What Happened...

ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of ProKidney Corp. (NASDAQ:PROK - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a...

ProKidney (NASDAQ:PROK) Sees Strong Trading Volume  - Time to Buy?

ProKidney (NASDAQ:PROK) Sees Strong Trading Volume - What's Next...

Hennion & Walsh Asset Management Inc. Has $3.37 Million Holdings in ProKidney Corp. $PROK

Hennion & Walsh Asset Management Inc. lifted its stake in shares of ProKidney Corp. (NASDAQ:PROK - Free Report) by 63.5% in the 4th quarter, according to its most recent Form 13F filing with the...

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

ProKidney Corp - Ordinary Shares - Class A

ProKidney Stock Skyrockets On Positive Trial Data; Citi Sees 60% Chance Of Success

Equity

Bullish Sentiment

Shares of ProKidney surged more than 500% on Tuesday following upbeat results from its Phase 2 REGEN-007 study and a price target upgrade from Citi.&nbsp;The company is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease (CKD) and diabetes.Citi raised its price target to $9 from $6 and maintained a ‘Buy’ rating, saying the early data “exceeded expectations.”&nbsp;The firm increased the probability of success for the program to 60%, citing statistically significant efficacy seen in Group 1 of the trial, which may support accelerated approval in Phase 3 subject to FDA feedback.The REGEN-007 study showed that kidney function decline was reduced by 78% in group 1 after rilparencel treatment.&nbsp;Patients who received two injections approximately three months apart experienced an improvement in their annual eGFR slope from -5.8 to -1.3 mL/min/1.73 m², representing a statistically and clinically meaningful difference.However, Bank of America was more cautious, reiterating its ‘Underperform’ rating and $1 price target.&nbsp;The firm flagged the absence of a sham comparator, lack of a conference call to discuss the data, and regulatory ambiguity. It stated that the stock’s sharp rally “looks overdone,” especially given that detailed data are likely to be withheld for a future medical meeting.ProKidney reported that no serious side effects were observed in the trial, and the safety results were consistent with earlier studies.&nbsp;Rilparencel already holds RMAT status from the FDA and is also being tested in a larger Phase 3 trial called PROACT 1.&nbsp;The company noted that early signals from REGEN-007 reinforce previously observed efficacy trends in high-risk patient subgroups.On Stocktwits, retail sentiment for <a href="https://stocktwits.com/symbol/PROK">ProKidney</a> was ‘extremely bullish’ amid ‘extremely high’ message volume.One user anticipated strong momentum ahead, saying they were “thinking 100% gain tomorrow.”<stembedurl>https://stocktwits.com/MarketMana/message/620282357</stembedurl>Another poster struck a more cautious but optimistic tone, noting that while they’d “love for this ticker and its well-deserving product [to have] a double-digit run,” biotech stocks often see profit-taking after big moves.&nbsp;They said short sellers could enter soon but saw long-term potential, saying, “If Phase III pans out and it gets FDA approval, it could make you a millionaire.”<stembedurl>https://stocktwits.com/nomendivitiae/message/620278285</stembedurl>ProKidney’s stock has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

The treatment, rilparencel, showed a 78% improvement in kidney function decline in one dosing group, with no serious safety issues reported, supporting its ongoing evaluation in a larger Phase 3 trial.

ProKidney Corp

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$PROK  early results are showing great promise. This is going to help so many people. I am in for the long haul.

king richard

$PROK  I am pretty sure they have enought money to get them through the trails next year. But I am sure they will need more if and when it gets FDA approval. Hopefully the price will be much hight then. I will keep holding until next summer when we find out

$PROK  Nice presentation , They have already showed that Kidney repair is possible with this drug. That was huge for me .

📅 CATALYST REMINDER | $PROK 
October 23, 2026 — Phase 2 Clinical Data 
ProKidney will present pooled Phase 2 rilparencel safety and efficacy findings at ASN Kidney Week. 
More details in our hub. 
#PROK #Biotech #KidneyWeek

Merlintrader Trading Pub

$PROK This  stock  will  be  good,  no  question  there.  But  I  think everyone  is  waiting  to  hear  how  this  drug/treatment  will  be  funded to  commercialization. I  could  see  an  ATM  funding  campaign  coming  soon,  but  before  or  after  results?

Kyle J

$PROK Excellent presentation...Some people may want this lower for selfish reasons but seems to me that a historic change in nephrology is taking shape at Prokidney.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PROK ProKidney Corp

Fundamentals

Latest PROK News